engleski

Bone markers reveal decreased collagen type I synthesis and change in bone turnover during bisphosphonate treatment in osteogenesis imperfecta

Continuous action of bone cells, i.e. remodeling of the skeleton, is reflected by measuring the products of their activity in serum or urine. Availability of methods for determination of bone markers has provided some data on bone turnover in osteogenesis imperfecta patients and the utility of bone markers in evaluation of bisphosphonate tretment. It has been demonstrated that procollagen type I propeptide was reduced in children with osteogenesis imperfecta in comparison to controls, but other bone markeres were not considerably different. In severely affected adults wih osteogenesis imperfecta bone resorption markers were increased, but also both normal and reduced concentrations were found. Treatment with bisphosphonates caused reduction of bone markeres. Results obtained in a group of 20 osteogenesis imperfecta children and adults were similar. Levels of procollagen were below or within the reference range for premenopausal women in the majority of patients which were younger than 15 years, although incrased concentrations would be expected due to intensive skeletal growth. Decreased procollagen in OI patients probably reflects less collagen type I formation and retarded skeletal growth. Effect of bisphosphonate therapy was observed as decrease in procollagen afeter commencement and as continuous decrease during one year therapy. Bone resorption in some children younger than 10 years was below the upper limit of reference range for premenopausal women, but increased in older patients. Similar to procollagen results, much higher levels of resorption markers characteristic of intensive growth and turnover would be expected, also suggesting growth impairment. It can be expected that clinical utility of bone markeres in osteogenesis imperfecta patients will be validated after more experience is gathered generated by bisphosphonate treatment and biochemical assessment. In comparison to other metabolic bone diseases, a benefit of a choice of specific bone marker and a degree of change in monitoring can be expected.

bone markers ; collagen type I ; bone turnover ; bisphosphonate treatment ; osteogenesis imperfecta

Rad je prezentiran na skupu 29Th European Symposium On Calcified Tissues.